04:44 AM EDT, 08/28/2026 (MT Newswires) -- Bayer (BAYN.F) said Friday it filed a marketing authorization application in Japan to expand the use of finerenone in chronic kidney disease, or CKD. The application is backed by results from the German drugmaker's phase 3 FIND-CKD trial in adults with non-diabetic CKD, in which the drug, in addition to standard of care, significantly delayed kidney disease progression and reduced cardiovascular-kidney events compared with placebo.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.